HOME > ARCHIVE
ARCHIVE
- Cost Should Be Calculated for Each Diagnosis Group: JHA Seminar
March 31, 2003
- MEDICAL DEVICES NEWS IN BRIEF
March 31, 2003
- If GE Use Will Rise Under DPC-based Flat-sum System?: Seminar
March 31, 2003
- DIAGNOSTIC NEWS IN BRIEF
March 31, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 31, 2003
- WORLD NEWS IN BRIEF
March 31, 2003
- JPMA President to Propose "Hybrid" NHI Price System
March 31, 2003
- Yamanouchi Discovers 3 New Target Genes for Antidiabetics
March 31, 2003
- JPMA Approves Plans to Strengthen Activities of Its Thinktank
March 31, 2003
-
March 31, 2003
- Tanabe Licenses Transmucosal Oral Fentanyl from Cephalon
March 31, 2003
- Predicting Disease Prevalence to Be Major Issue: JPMA Seminar
March 31, 2003
- GL for Treatment of H. pylori Infection Revised
March 31, 2003
- 1 in 3 GPs Rarely See MRs: Survey
March 31, 2003
- AstraZeneca to Study Proper Use of Iressa with IMSUT
March 31, 2003
- MR Activities Over-concentrated in GP market: MOSS Institute Survey
March 31, 2003
- Promoting Development of Venture Biz Stressed: Regenerative Medicine Seminar
March 31, 2003
- Reed Exhibitions Japan to Hold Bio Partnering Forum in May
March 31, 2003
- Methods of Drug Risk/Benefit Assessment Studied by RAD-AR Council Japan
March 31, 2003
- BUSINESS NEWS IN BRIEF
March 31, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
